You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

CLINICAL TRIALS PROFILE FOR TRANSDERM SCOP


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TRANSDERM SCOP

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00716014 ↗ Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita Completed Pachyonychia Congenita Project Phase 1 2008-01-01 Pachyonychia congenita (PC) is a rare, autosomal dominant keratin disorder affecting the nails, skin, oral mucosae, larynx, hair and teeth. Pathogenic mutations in keratin K6a, K6b, K16 or K17 act via a dominant negative mechanism, leading to manifestations of the disease. The most disabling PC symptom is a painful plantar blistering and keratoderma that requires use of ambulation devices in more than 50 percent of patients. Despite our understanding of the molecular basis of PC, current treatment is limited to mechanical removal of the thick calluses, non-specific topical keratolytics, and oral retinoids, none of which alleviates blistering or plantar pain satisfactorily. A public charity, PC Project, has been founded to support the development of treatments for PC (www.pachyonychia.org). In collaboration with this charity, a small company, TransDerm, Inc., has developed a small interfering RNA (siRNA) that specifically targets a mutation in one of the PC keratins, K6a. As this siRNA targets a single nucleotide mutation, it will only be effective against PC subjects harboring this specific mutation. There are currently only six known patients who carry this mutation in the International Pachyonychia Congenita Research Registry, but three of these patients live in Salt Lake City (a mother and two of her children). We propose to perform a Phase Ib clinical trial to test the safety and tolerability of TD101 in PC patients carrying an N171K mutation. We will complete treatment of the adult patient prior to recruitment of the minors.
NCT03029650 ↗ Scopolamine Patch Pharmacokinetics in Healthy Adults Completed University of Minnesota Phase 4 2016-11-01 The study to be performed will utilize already FDA-approved marketed products in healthy adults for the purpose to generate data for establishing rate of drug delivery of Transderm Scop® TDDS (transdermal drug delivery system) in healthy adults and to ensure safety of individuals utilizing these types of products.
NCT03029650 ↗ Scopolamine Patch Pharmacokinetics in Healthy Adults Completed University of Minnesota - Clinical and Translational Science Institute Phase 4 2016-11-01 The study to be performed will utilize already FDA-approved marketed products in healthy adults for the purpose to generate data for establishing rate of drug delivery of Transderm Scop® TDDS (transdermal drug delivery system) in healthy adults and to ensure safety of individuals utilizing these types of products.
NCT03029650 ↗ Scopolamine Patch Pharmacokinetics in Healthy Adults Completed University of Iowa Phase 4 2016-11-01 The study to be performed will utilize already FDA-approved marketed products in healthy adults for the purpose to generate data for establishing rate of drug delivery of Transderm Scop® TDDS (transdermal drug delivery system) in healthy adults and to ensure safety of individuals utilizing these types of products.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TRANSDERM SCOP

Condition Name

Condition Name for TRANSDERM SCOP
Intervention Trials
Motion Sickness 2
Pachyonychia Congenita 1
Prevention of Nausea Associated With Motion Sickness 1
Treatment of Nausea Associated With Motion Sickness 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TRANSDERM SCOP
Intervention Trials
Motion Sickness 3
Pachyonychia Congenita 1
Nails, Malformed 1
Nausea 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TRANSDERM SCOP

Trials by Country

Trials by Country for TRANSDERM SCOP
Location Trials
United States 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TRANSDERM SCOP
Location Trials
Ohio 3
Iowa 1
Utah 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TRANSDERM SCOP

Clinical Trial Phase

Clinical Trial Phase for TRANSDERM SCOP
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TRANSDERM SCOP
Clinical Trial Phase Trials
Completed 2
Terminated 1
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TRANSDERM SCOP

Sponsor Name

Sponsor Name for TRANSDERM SCOP
Sponsor Trials
Repurposed Therapeutics, Inc. 2
Pachyonychia Congenita Project 1
University of Minnesota 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TRANSDERM SCOP
Sponsor Trials
Other 4
Industry 2
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.